Gumokimab is the successful eighth drug, which was independently developed by It's coming (With the adoption of six of them already to put it on the market), which is also the third innovative drug not intended for tumor therapy, after the needle (PCSK9) and Badarocimab (IL-12/IL-23), which reaches the marketing stage.
Gumokimab has been evaluated in four clinical studies that included patients with severe to severe wealthy psoriasis, including a pivotal clinical trial of the third stage (AK111-301) and three supportive studies.
Effective data shows that Gwokimab works quickly, With a marked treatment improved just two weeks after treatment.
S.Short term effectiveness: In the 12th week, the PASI 75 response rate is approaching 96%, with the SPGA 0/1 response rate approaching 90%. The PASI 90 response rate was close to 80%, the PASI response rate exceeded 100%, and all effectiveness of the event was greatly superior to the imaginary drug group. More than 80% of patients achieved PASI 90 response, and about 50% of them achieved PASI 100 response.
Long -term event: The unilateral therapy has shown a sustainable effectiveness for 52 weeks, with a constant improvement and long -term maintenance. By week 52, the PASI 75 response rate is approaching 100%, with SPGA 0/1 response rates. Pasi 90 and PASI 100 improved to nearly 90% and 65%, respectively.
safety: During both the phase of imaginary therapy and a comprehensive treatment stage, the incidence of the incidence of the events was compared to the two groups of the Joachimab and the imaginary therapy, as the Joachimab group showed a little lower values in all standards.
Mr
doctor.
Psoriasis patients are in urgent need of better treatment options, and It's coming This is treated with the use of “Ebarocimb” and “Gokimab” real estate, which targets different pathological paths and complements each other in treatment, allowing us to meet a wide range of patients' needs.
And with the successful launch of products such as Ibronocimab (PCSK9), Nadarokimab (IL-12/IL-23), and Jokimab (IL-17), as well as effective progress of innovative drugs that are not targeted that target multiple use, including Mandinocamab (Mandinocamab) . IL-4R), Dual Privacy Antibodies IL-4R/St2, and neurological degenerative treatments, the vitality of our product group is increasing and synergy. Stronger. This progress is greatly enhanced Aksu Global competitiveness in the business sector is not related to tumors. Meanwhile, and with the development and improvement of a more systematic, accurate and efficient marketing team, we have formulated a comprehensive and scientific marketing strategy for our products that are not related to tumors. This strategy is designed to accelerate the expansion of the market, and to put our tumors unrelated as a strong engine for the company's high -quality growth.
About Gocamab
Gumokimab is an innovative and compatible anti-human antibiotic body (Interleukin-17) has been developed by It's coming To treat autoimmune diseases such as psoriasis and busts. IL-17 is a pro-inflammatory cytokin that is mainly excreted by the TH17 stimulant cells, which is associated with its future (IL-17R) on cell surfaces, mediates inflammatory immune responses and plays a decisive role in causing psoriasis and busts. Gumokimab specifically targets IL-17, and prevents the course of IL-17/IL-17R signals to prevent the appearance and development of relevant inflammatory immune responses. Currently, the NDA Agreement for Gumokimab has been accepted in high -end psalm cases by NMPA, and the third stage of clinical trials continues to treat installment spondylitis.
on It's coming
It's coming (HKEX: 9926.hk) is a leading biological company committed to research, development, manufacturing and marketing of the first or best innovative biological drugs in the world. The company was established in 2012, and it has established a unique and integrated system for creating research and development with a comprehensive platform for the development of drugs (ACE Platform) and the technology of developing Tetrabody as a core, which is a system compatible with GMP and a marketing system with advanced operating mode, It gradually evolved into a vital pharmaceutical company capable of competing globally and focuses on innovative solutions. With an integrated multi -function platform, It's coming Internally works on a strong group of more than 50 innovative origin in the fields of cancer, autoimmune diseases, infections, metabolic diseases and other major diseases. Among them, 22 candidates have entered clinical trials (including 11 dual -specific antifackets and dual -privacy accompanying). In addition, there are 5 new drugs that are commercially available, and 5 new drugs through 7 indicators are currently undergoing organizational review. Through effective innovation and penetration in the field of research and development, It's coming The superior global resources, the development of the first and best new drugs in their class, provide affordable antibodies at affordable prices for patients all over the world, constantly create more commercial and social values to become a leading vital pharmaceutical institution.
For more information, please visit https://www.eksobio.com/en/about-us/corporate-pryf/ And follow us on YandinAnd X .
